Consultation between forensic and clinical pathologists for histopathology examination after forensic autopsy.

The magnitude of the diagnostic benefit conferred by performing histopathological examinations after medico-legal/forensic autopsies remains debatable. We have tried to address this issue by reviewing a series of histopathology referrals concerning medico-legal autopsies in real-world routine practice. We present an audit of the consultations provided to forensics by clinical pathologists at our institute between 2015 and 2018. Over this period, 493 post-mortem examinations were performed by forensic pathologists. Of these cases, 52 (11%) were referred for histopathology. Gross assessment was requested in 22/52 (42%) cases. Histopathology examination was performed on single organs in 15/52 (29%) cases, primarily on the lung and heart, whereas parenchymatous multi-organ analysis was carried out in 14/52 (27%) cases. Bone-marrow sampling was studied in 4/52 (8%) cases. Immunohistochemistry was needed in 16/52 (31%) cases, special stains in 9/52 (21%) cases and molecular analysis in 4/52 (8%) cases. Focusing on technical processes, standard methodology on pre-analytical procedures was changed in 10/52 (19%) cases in order to answer specific diagnostic questions. We showed that although most of the time the diagnosis is clear by the end of dissection on the basis of the macroscopic findings, histopathology can provide, modify or confirm the cause of death in many medico-legal/forensic cases. Therefore, it is desirable that forensic pathologists and clinical pathologists establish robust working relationships in a cooperative environment. We conclude that it is important to implement guidelines based on real-world routine practice in order to identify cases where histopathology can provide useful contributions, which in our experience applied to 11% of forensic cases.

Fatal, Intentional Overdose of Ranolazine: Post-Mortem Distribution of Parent Drug and its Major Metabolite.

PURPOSE: Ranolazine is a selective inhibitor of the late inward sodium-current, approved for the treatment of chronic angina. Here, we report a case of a possibly suicidal death due to acute ranolazine overdosing. A 41-year-old woman was found unconscious by her son and was urgently admitted to the Intensive Care Unit. She had ingested an unknown amount of ranolazine tablets. Seventeen hours after admission, the patient died. An autopsy was performed 4 days post-mortem. METHODS: A routine screening analysis for drugs of abuse and medicinal drugs performed by liquid chromatography ion trap mass spectrometry on autopsy samples of biological fluids did not detect any relevant presence of toxicologically relevant compounds, but ranolazine. A quantitative analysis was then carried out by liquid chromatography- QqQ mass spectrometry in order to quantify ranolazine and its major metabolite O-desmethyl-ranolazine in biological fluids and organs. RESULTS: Ranolazine concentrations in biological fluids were as follows: cardiac blood, 19.5 µg/mL; femoral blood, 12.3 µg/mL; bile, 0.87 µg/mL and vitreous humor, 15.4 µg/mL. For O-desmethyl-ranolazine the concentrations in cardiac blood, femoral blood, bile and vitreous were 10.7 µg/mL; 9.6 µg/mL; 11,103 µg/mL and 11.4 µg/mL, respectively. CONCLUSIONS: The cause of death was attributed to ranolazine overdosing. To the best of our knowledge, this is the first report of a fatality associated with ranolazine, in which the postmortem distribution of ranolazine and its metabolite has been quantitatively assessed. The present study can therefore provide useful information for interpretation of the causes and mechanisms of death in ranolazine associated fatalities.